Overview

Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)

Status:
Completed
Trial end date:
2006-07-18
Target enrollment:
Participant gender:
Summary
This study is requested by PMDA to confirm the optimal dose for THR (total hip replacement).
Phase:
Phase 3
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Fondaparinux
PENTA